Previously Senior Vice President and Managing Director European Operations, Mancuso now oversees Patheon's global commercial manufacturing platform
Jan. 25, 2012
/PRNewswire/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that
has been promoted to President, Global Commercial Operations and Chief Manufacturing Officer, responsible for Patheon's global commercial manufacturing operations . Ms. Mancuso will assume responsibility for all of Patheon's commercial operating units in
. In her previous role as Senior Vice President and Managing Director European Operations, Ms. Mancuso managed the company's commercial manufacturing operations outside of
"Antonella's demonstrated success focusing on the customer, on quality, and on margins is in direct alignment with our company strategy and directly supports the needs of our customers, our employees and our shareholders. I am excited about this opportunity to unify our manufacturing services business and leverage best practices across our business," stated
, Patheon's Chief Executive Officer.
Ms. Mancuso joined Patheon in 2001 as Production Manager of Patheon's facility in Monza,
, becoming Site Director in
. She has held other positions with increasing responsibility culminating with her appointment to her new position as President, Global Commercial Operations and Chief Manufacturing Officer. Prior to joining Patheon, Ms. Mancuso held progressively senior roles in production and manufacturing during her six years at Bristol-Myers Squibb in
. Antonella has also worked at Select Pharma and Bioprogress. She holds a degree in Pharmaceutical Chemistry and Technology from La Sapienza University of
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, soft gel, solid and liquid forms.